Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 4 4Phase 2 4

Status

Terminated 2Completed 2

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Neoplasms 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Triptorelin Pamoate × Clear all
NCT01673984 2025-05-23

GREAT

Ipsen

Phase 4 Terminated
27 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT01753297 2020-12-09

PRIORITI

Ipsen

Phase 4 Completed
226 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT02749825 2016-04-25

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Pharmatech

Phase 4 Terminated
41 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01161563 2013-09-06

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Watson Pharmaceuticals

Phase 4 Completed
118 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡